All News

GCA temporal artery

Drug-Free Remission in Giant Cell Arteritis is Uncommon

Jack Cush, MD

A Spanish retrospective registry study of patients with giant cell arteritis (GCA) found that 3-4 years after diagnosis, only 21% of patients with GCA successfully reached the sustained drug-free remission (SDFR).

Read Article
young%20doctors.jpg (keep)

Way Behind in Pediatric Rheumatology

Jack Cush, MD

While adult rheumatology fellowships have surged in popularity and become quite competitive, more than half of pediatric rheumatology fellowship positions went unfilled in 2024, according to the National Resident Matching Program (NRMP). 

Read Article
RheumNow Podcast square

Don’t Buy Guitars (12.6.2024)

Jack Cush, MD

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

Read Article
DLE discoid lupus

Challenge in Measuring Cutaneous Lupus Activity and Severity

Jack Cush, MD

JAMA Dermatology features a discussion by Drs. McMichael and Frey on measuring lupus skin disease in clinical trials and practice using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI).

Read Article
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/SMKx1LnBB1 https://t.co/96u5YuvyIf

Links:

Dr. John Cush RheumNow ( View Tweet)
Ozempic will change rheumatology @drdavidliew Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/4gujykjDCa https://t.co/RLG1vA57kC
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Shifting Trends in Initial RA Treatment Approaches A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for RA over two decades in the US. https://t.co/XlMXkuBBVN https://t.co/AHi3DG0aFV https://t.co/vNLF4Ft1GR

Links:

Dr. John Cush RheumNow ( View Tweet)
UK study compared 16,634 female RA pts vs 65,448 controls and found all RA women at incr risk for VTE (thrombosis)[aHR=1.52) irrespective of estrogen contraceptives/HRT. Contraceptives did not increase VTE risk (aHR 2.32; 0.92, 5.85, p=0.08) #ACR24 https://t.co/AzBXI0W5dv https://t.co/Q4TaKq2ReC

Links:

Dr. John Cush RheumNow ( View Tweet)
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/ASErsKTNQ6 https://t.co/d1BRW92vju

Links:

Dr. John Cush RheumNow ( View Tweet)
Ozempic will change rheumatology @drdavidliew Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/lELDs7Yy5W https://t.co/wuXZR4vkx8
Dr. John Cush RheumNow ( View Tweet)
Cyclophosphomide vs Mycophenolate vs Tacrolimus in Lupus Nephritis Dr. Mike Putman discusses abstract 0670, presented at #ACR24. https://t.co/aLzsSSOmML https://t.co/XrEtNZAgHI

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. Content is chosen by RheumNow & its facult.y

Dr. John Cush RheumNow ( View Tweet)

RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

#ACR24 - Day 3 Report Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations. https://t.co/Dif4EUi30b https://t.co/4hfEJ1ef73

Links:

Dr. John Cush RheumNow ( View Tweet)
GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have transformed the treatment landscape for type 2 diabetes and obesity. #ACR24 https://t.co/6QqEH8X2VJ https://t.co/Ch2i9zZYii

Links:

Dr. John Cush RheumNow ( View Tweet)
ORAL Surveillance - Is Statin Use the Problem/Solution? The findings from ORAL Surveillance Study have been a dominant conversation at #ACR24, with the seminal findings and subsequent analyses a target of debate. https://t.co/Nn9KSL4dlv https://t.co/gHPwK35eEd

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis disease… https://t.co/SnqvElwk0B https://t.co/A5mJbpmB5P

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

Dr. John Cush RheumNow ( View Tweet)

Are Emulation Trials a Fantasy? Are these ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)? https://t.co/x6NogGQksW https://t.co/f8o8N55tlJ

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×